Geode Capital Management
CTXR icon

Geode Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Geode Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Sell
215,537
-30,621
-12% -$20.7K ﹤0.01% 4041
2026
Q1 		$222K Buy
246,158
+118,625
+93% +$95.8K ﹤0.01% 3874
2025
Q4 		$99.1K Buy
127,533
+7,762
+6% +$9.71K ﹤0.01% 4100
2025
Q3 		$149K Buy
119,771
+43,676
+57% +$60.9K ﹤0.01% 4020
2025
Q2 		$121K Sell
76,095
-13,180
-15% -$12.1K ﹤0.01% 4014
2025
Q1 		$133K Buy
89,275
+12,769
+17% +$30.6K ﹤0.01% 3950
2024
Q4 		$306K Buy
76,506
+1,348
+2% +$9.08K ﹤0.01% 3754
2024
Q3 		$941K Buy
75,158
+9,306
+14% +$157K ﹤0.01% 3373
2024
Q2 		$961K Sell
65,852
-51,968
-44% -$931K ﹤0.01% 3321
2024
Q1 		$2.64M Buy
117,820
+6,624
+6% +$121K ﹤0.01% 3010
2023
Q4 		$2.1M Buy
111,196
+4,181
+4% +$79.3K ﹤0.01% 3085
2023
Q3 		$1.83M Buy
107,015
+2,694
+3% +$64K ﹤0.01% 3099
2023
Q2 		$3.13M Buy
104,321
+50,770
+95% +$1.67M ﹤0.01% 2947
2023
Q1 		$1.57M Buy
53,551
+246
+0.5% +$7.09K ﹤0.01% 3133
2022
Q4 		$1.05M Buy
53,305
+373
+0.7% +$10.2K ﹤0.01% 3316
2022
Q3 		$1.6M Buy
52,932
+530
+1% +$14.6K ﹤0.01% 3163
2022
Q2 		$1.21M Sell
52,402
-38,484
-42% -$1.06M ﹤0.01% 3340
2022
Q1 		$4.07M Buy
90,886
+8,917
+11% +$352K ﹤0.01% 2918
2021
Q4 		$3.15M Sell
81,969
-3,276
-4% -$149K ﹤0.01% 3143
2021
Q3 		$4.33M Buy
85,245
+9,025
+12% +$453K ﹤0.01% 2995
2021
Q2 		$6.63M Buy
76,220
+42,052
+123% +$2.53M ﹤0.01% 2739
2021
Q1 		$1.52M Buy
34,168
+28,370
+489% +$1.13M ﹤0.01% 3387
2020
Q4 		$147K Hold
5,798
– – ﹤0.01% 3975
2020
Q3 		$150K Buy
5,798
+3,028
+109% +$85.6K ﹤0.01% 3803
2020
Q2 		$78K Buy
+2,770
New +$60.6K ﹤0.01% 3912

Other funds holding CTXR

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $235M AUM 31.01% 1-Year Est. Return

Geode Capital Management's CTXR Position: Q2 2026 in Review

Geode Capital Management reduced its Citius Pharmaceuticals (CTXR) stake by 12% in Q2 2026, selling an estimated $20.7K and leaving 215,537 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #4041.

Geode Capital Management first reported a position in CTXR in Q2 2020 and has held it in 25 quarters since. The position peaked at $6.63M in Q2 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Geode Capital Management held 215,537 shares of Citius Pharmaceuticals worth $130K as of Q2 2026.
  • Geode Capital Management sold 30,621 Citius Pharmaceuticals shares in Q2 2026, an estimated $20.7K.
  • Citius Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4041 holding.
  • Geode Capital Management first reported a position in Citius Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Geode Capital Management's Citius Pharmaceuticals position peaked at $6.63M in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.